Verrica completes enrollment in Phase 3 COVE-2 trial of YCANTH for common warts, sees data in Q1 2027
VRCA•COVE-3 passes halfway point
COVE-3, the second pivotal Phase 3 trial, passed 50% enrollment; topline data remain expected in mid-2027.
The program targets a label expansion into common warts, a market with no FDA-approved prescription drug therapies.
Phase 3 COVE-2 enrollment completed
Verrica completed enrollment in COVE-2, the first pivotal Phase 3 trial of YCANTH for common warts.
Topline results have not been presented; data are expected in Q1 2027.
An interim power review supported full enrollment with no added patients, keeping the study blinded.
